Four Lojuxta® distribution agreements signed in Middle East

Oral health has been isolated from traditional healthcare and health policy for too long fuelling an oral health crisis according to a Lancet Series.

Amryt has announced the signing of four further distribution agreements for Lojuxta® (lomitapide) across the Middle East, where the incidence of Homozygous Familial Hypercholesterolaemia (“HoFH”), the rare cholesterol disorder treated by Lojuxta, is relatively high.

The distribution agreements have been signed with Al Hafez Trading Establishment, which operates in Kuwait, Ebn Sina Medical, Muscat Pharmacy and Stores in Oman, and Goro Healthcare of the UAE and Bahrain. These agreements extend Amryt’s distribution network in the region and will provide HoFH patients with better access to care.

Since November 2017 Amryt has signed nine new distribution agreements for Lojuxta. The Company holds an exclusive licence to sell Lojuxta across Europe, the Middle East, Turkey, Israel, Russia, the Commonwealth of Independent States, and the Balkan states. The recent expansion of the licence agreement has increased the total number of addressable patients in Amryt’s territories by approximately 25%.

Joe Wiley, CEO of Amryt Pharma, commented: “These agreements will ensure that we can respond effectively to physician requests for Lojuxta. The Middle East has a higher HoFH patient population per capita than Europe and we look forward to working closely with our new distribution partners to improve patient outcomes.”